Anima Biotech to Present at 19th Annual Biotech in Europe Forum Hosted by Sachs Associates
Details regarding the panel discussion are as follows:
BERNARDSVILLE, N.J., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Anima Biotech, the leader in the discovery of drugs that control mRNA translation, today announced the company will present at Sachs Associates’ 19th Annual Biotech in Europe Forum taking place in Basel, Switzerland, September 25 – 26.
Yochi Slonim, Co-founder and Chief Executive Offer of Anima Biotech, will provide an overview of the company’s Translation Control Therapeutics technology for the discovery of small molecule drugs that control mRNA translation.
In addition to his presentation, Mr. Slonim will also participate on a “Platform Technologies & Novel Therapeutics” panel.
Details regarding the company’s presentation are as follows:
Event: 19th Annual Biotech in Europe Forum
Date: Wednesday, September 25, 2019
Time: 12:45 p.m. CEST
Room: Darwin
Venue: Congress Center Basel
Details regarding the panel discussion are as follows:
Event: Platform Technologies & Novel Therapeutics Panel
Date: Wednesday, September 25, 2019
Time: 10:45 a.m. CEST
About Anima Biotech
Anima Biotech is advancing Translation Control Therapeutics, the first platform for the discovery of small molecule drugs that control mRNA translation as a new strategy against many diseases. With novel biology that monitors the translation of proteins and proprietary cloud-based analysis software, we identify drug candidates that modulate a target protein’s production. We develop a pipeline across therapeutic areas and partner with Pharma for their targets including our $1B+ collaboration with Lilly for the discovery and development of translation inhibitors of several targets. Our approach was further validated with 5 granted patents, 14 peer reviewed publications and 17 scientific collaborations. To learn more about us, visit https://www.animabiotech.com
Media Contact:
Andrew Mielach
LifeSci Public Relations
+1.646.876.5868
[email protected]
